Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz-Ares; Mikhail Dvorkin; Yuanbin Chen; Bernd Lamprecht; et al.

doi:10.1016/S0140-6736(19)32222-6

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz-Ares
, Mikhail Dvorkin
, Yuanbin Chen
, Bernd Lamprecht
, et al.

Department of Internal Medicine 4 - Pneumology and Infectious Diseases

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1929-1939
Number of pages	11
Journal	The Lancet
Volume	394
Issue number	10212
DOIs	https://doi.org/10.1016/S0140-6736(19)32222-6
Publication status	Published - 23 Nov 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Fields of science

301 Medical-Theoretical Sciences, Pharmacy
302 Clinical Medicine

Access to Document

10.1016/S0140-6736(19)32222-6

Cite this

@article{8b8f8edb50b34293a515acd08b036d20,

title = "Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial",

author = "Luis Paz-Ares and Mikhail Dvorkin and Yuanbin Chen and Bernd Lamprecht and \{et al.\}",

year = "2019",

month = nov,

day = "23",

doi = "10.1016/S0140-6736(19)32222-6",

language = "English",

volume = "394",

pages = "1929--1939",

journal = "The Lancet",

issn = "1474-547X",

number = "10212",

}

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. / Paz-Ares, Luis; Dvorkin, Mikhail; Chen, Yuanbin et al.
In: The Lancet, Vol. 394, No. 10212, 23.11.2019, p. 1929-1939.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

AU - Paz-Ares, Luis

AU - Dvorkin, Mikhail

AU - Chen, Yuanbin

AU - Lamprecht, Bernd

AU - et al., null

PY - 2019/11/23

Y1 - 2019/11/23

UR - https://www.ncbi.nlm.nih.gov/pubmed/31590988

UR - https://www.scopus.com/pages/publications/85075219567

U2 - 10.1016/S0140-6736(19)32222-6

DO - 10.1016/S0140-6736(19)32222-6

M3 - Article

SN - 1474-547X

VL - 394

SP - 1929

EP - 1939

JO - The Lancet

JF - The Lancet

IS - 10212

ER -

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

UN SDGs

Fields of science

Access to Document

Other files and links

Cite this